8 research outputs found
MYC amplifications are common events in childhood osteosarcoma.
Funder: Bone Cancer Research Trust; Id: http://dx.doi.org/10.13039/100011719Funder: The Tom Prince Cancer TrustFunder: Wellcome Trust; Id: http://dx.doi.org/10.13039/100010269Funder: Jean Shanks Foundation – Pathological Society Clinical FellowshipFunder: UCL Experimental Cancer CentreFunder: UCLH Biomedical Research Centre; Id: http://dx.doi.org/10.13039/501100012317Funder: National Institute for Health Research; Id: http://dx.doi.org/10.13039/501100000272Osteosarcoma, the most common primary malignant tumour of bone, affects both children and adults. No fundamental biological differences between paediatric and adult osteosarcoma are known. Here, we apply multi-region whole-genome sequencing to an index case of a 4-year-old child whose aggressive tumour harboured high-level, focal amplifications of MYC and CCNE1 connected by translocations. We reanalysed copy number readouts of 258 cases of high-grade osteosarcoma from three different cohorts and identified a significant enrichment of focal MYC, but not CCNE1, amplifications in children. Furthermore, we identified four additional cases of MYC and CCNE1 coamplification, highlighting a rare driver event which warrants further investigation. Our findings indicate that amplification of the MYC oncogene is a major driver of childhood osteosarcoma, while CCNE1 appears recurrently amplified independent of age
Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
Therapy-related myeloid neoplasms (TMN) constitute one of the most challengingcomplications of cancer treatment.1 Whilst understanding of TMN pathogenesis remains fragmentary, genomic studies in adults have thus far refuted the notion that TMN simply result from cytotoxin-induced DNA damage.2–4 Analysis of the preclinical evolution of a limited number of adult TMN have retraced the majority of cases to clonal haematopoiesis (CH) that predates cytotoxic treatment and lacks the mutational footprint of genotoxic therapies.2–6 Balanced translocations,
generally attributed to treatment with topoisomerase II inhibitors, are implicated in a minority of TMN.1 TMN is a leading cause of premature death in childhood cancer survivors, and affects 7-11% of children treated for high-risk neuroblastoma and sarcoma.7,8 However, the origin of pediatric TMN remains unclear. Targeted sequencing of known cancer genes detects CH in ~4% of children following cytotoxic treatment,6,9 whereas CH is vanishingly rare in young individuals in the general population.10,11 Moreover, to our knowledge, no cases of childhood TMN have been retraced to pretreatment CH. In light of these observations, we asked whether a broader driver landscape had eluded targeted CH screens in pediatric cancer patients and/or whether therapy-induced mutagenesis may be an under-recognised catalyst of CH and TMN in this patient group
Recommended from our members
Reconstructing Chromothriptic Chromosomes in Oesophageal Adenocarcinomas
The epigenetic landscape is regulated by a myriad of factors. This regulation ranges from functional compartmentalisation of genomic sequences into topologically associating domains, to chromosome looping, to short-range promoter-enhancer interactions. The underlying genome sequence contributes to this regulation, likely at a variety of scales, however the extent of this contribution is not fully understood. Chromothripsis is a localised catastrophic genome shattering event that can be used to study how the underlying genomic sequence affects this higher order structuring. Since chromothripsis tends to affect only one of the two alleles, in every cell a direct comparison can be made between the wild-type chromosome and the chromothriptic chromosome. The wild-type chromosome represents the genome sequence and structure before reshuffling and the chromothriptic derivative chromosome can be used to query the direct effects of this reshuffling.
Chromothripsis has been seen in up to 32% of cases of oesophageal adenocarcinomas. Therefore, patient-derived oesophageal adenocarcinoma organoids with evidence of chromothripsis restricted to one allele were used to better understand how the genome is regulated. Complex regions of structural variation between alleles in cancer genomes coupled with subclonal variants means haplotype-aware de novo assemblies are essential for contiguous cancer genome assemblies. Our method takes haplotype blocks and assigns PacBio circular consensus sequencing reads to the appropriate allele using B-allele frequencies of single nucleotide polymorphisms and presence of structural variants. The chromosomes are then assembled separately and scaffolded using Hi-C reads, which we also haplotype resolve. This produces contiguous assemblies, even on chromosomes with over 900 structural rearrangements compared to the reference genome. This methodology has been used to reconstruct chromothriptic derivative chromosomes and the associated wild-type chromosomes in five organoid models, as well as other chromosomes with complex rearrangements. All types of structural variant have been reconstructed, other than tandem duplications which are collapsed by current assembly tools.
With these cancer-specific reference assemblies, the epigenome of the chromothriptic and wild-type chromosomes can be profiled. Hi-C chromosome capture has been used to study topologically associated domains; ATAC-seq to study chromatin accessibility; ChIP-seq to identify CTCF binding and histone modifications (H3K27me3, H3K4me3, H3K27ac) and Iso-seq to phase long read transcripts to their respective chromosomes. There are widespread differences between the chromothriptic and wild-type chromosomes for each epigenetic mark. This indicates that the shattering of the chromosome has dramatic consequences for gene regulation, far beyond what we see when comparing two wild-type alleles of the same chromosome. It highlights that, while underlying genome sequence has a fundamental role in gene regulation, the epigenetic context of that sequence also has a profound impact. The work done to assemble these chromosomes allows for unprecedented insight into the regulatory impact of structural variation
Drivers underpinning the malignant transformation of giant cell tumour of bone.
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3 family of histone genes H3-3A or H3-3B; however, the same mutation is occasionally found in primary malignant bone tumours which share many features with the benign variant. Moreover, lung metastases can occur despite the absence of malignant histological features in either the primary or metastatic lesions. Herein we investigated the genetic events of 17 GCTBs including benign and malignant variants and the methylation profiles of 122 bone tumour samples including GCTBs. Benign GCTBs possessed few somatic alterations and no other known drivers besides the H3.3 mutation, whereas all malignant tumours harboured at least one additional driver mutation and exhibited genomic features resembling osteosarcomas, including high mutational burden, additional driver event(s), and a high degree of aneuploidy. The H3.3 mutation was found to predate the development of aneuploidy. In contrast to osteosarcomas, malignant H3.3-mutated tumours were enriched for a variety of alterations involving TERT, other than amplification, suggesting telomere dysfunction in the transformation of benign to malignant GCTB. DNA sequencing of the benign metastasising GCTB revealed no additional driver alterations; polyclonal seeding in the lung was identified, implying that the metastatic lesions represent an embolic event. Unsupervised clustering of DNA methylation profiles revealed that malignant H3.3-mutated tumours are distinct from their benign counterpart, and other bone tumours. Differential methylation analysis identified CCND1, encoding cyclin D1, as a plausible cancer driver gene in these tumours because hypermethylation of the CCND1 promoter was specific for GCTBs. We report here the genomic and methylation patterns underlying the rare clinical phenomena of benign metastasising and malignant transformation of GCTB and show how the combination of genomic and epigenomic findings could potentially distinguish benign from malignant GCTBs, thereby predicting aggressive behaviour in challenging diagnostic cases. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.info:eu-repo/semantics/publishe
Drivers underpinning the malignant transformation of giant cell tumour of bone
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3 family of histone genes H3-3A or H3-3B; however, the same mutation is occasionally found in primary malignant bone tumours which share many features with the benign variant. Moreover, lung metastases can occur despite the absence of malignant histological features in either the primary or metastatic lesions. Herein we investigated the genetic events of 17 GCTBs including benign and malignant variants and the methylation profiles of 122 bone tumour samples including GCTBs. Benign GCTBs possessed few somatic alterations and no other known drivers besides the H3.3 mutation, whereas all malignant tumours harboured at least one additional driver mutation and exhibited genomic features resembling osteosarcomas, including high mutational burden, additional driver event(s), and a high degree of aneuploidy. The H3.3 mutation was found to predate the development of aneuploidy. In contrast to osteosarcomas, malignant H3.3-mutated tumours were enriched for a variety of alterations involving TERT, other than amplification, suggesting telomere dysfunction in the transformation of benign to malignant GCTB. DNA sequencing of the benign metastasising GCTB revealed no additional driver alterations; polyclonal seeding in the lung was identified, implying that the metastatic lesions represent an embolic event. Unsupervised clustering of DNA methylation profiles revealed that malignant H3.3-mutated tumours are distinct from their benign counterpart, and other bone tumours. Differential methylation analysis identified CCND1, encoding cyclin D1, as a plausible cancer driver gene in these tumours because hypermethylation of the CCND1 promoter was specific for GCTBs. We report here the genomic and methylation patterns underlying the rare clinical phenomena of benign metastasising and malignant transformation of GCTB and show how the combination of genomic and epigenomic findings could potentially distinguish benign from malignant GCTBs, thereby predicting aggressive behaviour in challenging diagnostic cases. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.status: publishe
Drivers underpinning the malignant transformation of giant cell tumour of bone
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique mutation in the H3.3 family of histone genes H3‐3A or H3‐3B; however, the same mutation is occasionally found in primary malignant bone tumours which share many features with the benign variant. Moreover, lung metastases can occur despite the absence of malignant histological features in either the primary or metastatic lesions. Herein we investigated the genetic events of 17 GCTBs including benign and malignant variants and the methylation profiles of 122 bone tumour samples including GCTBs. Benign GCTBs possessed few somatic alterations and no other known drivers besides the H3.3 mutation, whereas all malignant tumours harboured at least one additional driver mutation and exhibited genomic features resembling osteosarcomas, including high mutational burden, additional driver event(s), and a high degree of aneuploidy. The H3.3 mutation was found to predate the development of aneuploidy. In contrast to osteosarcomas, malignant H3.3‐mutated tumours were enriched for a variety of alterations involving TERT, other than amplification, suggesting telomere dysfunction in the transformation of benign to malignant GCTB. DNA sequencing of the benign metastasising GCTB revealed no additional driver alterations; polyclonal seeding in the lung was identified, implying that the metastatic lesions represent an embolic event. Unsupervised clustering of DNA methylation profiles revealed that malignant H3.3‐mutated tumours are distinct from their benign counterpart, and other bone tumours. Differential methylation analysis identified CCND1, encoding cyclin D1, as a plausible cancer driver gene in these tumours because hypermethylation of the CCND1 promoter was specific for GCTBs. We report here the genomic and methylation patterns underlying the rare clinical phenomena of benign metastasising and malignant transformation of GCTB and show how the combination of genomic and epigenomic findings could potentially distinguish benign from malignant GCTBs, thereby predicting aggressive behaviour in challenging diagnostic cases. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland